Publication:
Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma

dc.contributor.buuauthorAtalay, Fatma Öz
dc.contributor.buuauthorVuruşkan, Berna Aytaç
dc.contributor.buuauthorVuruşkan, Hakan
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentCerrahi Patoloji Ana Bilim Dalı
dc.contributor.departmentÜroloji Ana Bilim Dalı
dc.contributor.researcheridAAH-9746-2021
dc.contributor.scopusid15623010600
dc.contributor.scopusid57053559100
dc.contributor.scopusid6507328150
dc.date.accessioned2023-06-06T06:23:15Z
dc.date.available2023-06-06T06:23:15Z
dc.date.issued2015-11-22
dc.description.abstractThe study investigated immunoexpression of amyloid A (AA) in clear cell renal cell carcinoma (CCRCC) and evaluated its clinicopathologic correlation, particularly in disease progression. Expression of AA protein was evaluated in patients with CCRCC by immunohistochemistry. 146 cancerous tissue samples from 86 male and 60 female patients were studied. The relationship between AA protein expression and TNM stage, nuclear grade, renal capsule invasion, perirenal invasion, and survival of the patients were assessed. Thirty four percent of CCRCC cases were AA positive. The positive AA immunoexpression was related to higher Fuhrman nuclear grade, presence of perirenal invasion of the tumor, and poor survival of patients with CCRCC. There was not any statistically significant difference between patients' gender, status of capsule invasion, and stages of the tumor in terms of AA immunoexpression. Tumor stage (Hazard ratio (HR) = 7.76 (95% CI: 2.43-24.8) for stage 3 and HR = 29.9 (95% CI: 6.97-128.32) for stage 4) and AA immunoexpression (HR = 2.16 (95% CI: 1.01-4.64) were found to be associated with survival of the patients with CCRCC in Cox regression analysis. Immunoexpression of AA was increased in high grade CCRCCs. Immunoexpression of AA was associated with poor survival in patients with CCRCC. Thus, AA staining might be used as a useful immunohistological marker for the prediction of poor prognosis in renal cell cancer.
dc.identifier.citationAtalay, F. Ö. vd. (2016). "Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma". APMIS, 124(4), 257-262.
dc.identifier.endpage262
dc.identifier.issn0903-4641
dc.identifier.issn1600-0463
dc.identifier.issue4
dc.identifier.pubmed26750935
dc.identifier.scopus2-s2.0-84954158599
dc.identifier.startpage257
dc.identifier.urihttps://doi.org/10.1111/apm.12499
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/apm.12499
dc.identifier.urihttp://hdl.handle.net/11452/32926
dc.identifier.volume124
dc.identifier.wos000372895700003
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherWiley
dc.relation.journalAPMIS
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectImmunology
dc.subjectMicrobiology
dc.subjectPathology
dc.subjectAmyloid A
dc.subjectPerirenal invasion
dc.subjectPrognosis
dc.subjectRenal cell carcinoma
dc.subjectStage
dc.subjectSurvival serum
dc.subjectSAA
dc.subjectProtein
dc.subjectCancer
dc.subjectProteomics
dc.subjectLung
dc.subject.emtreeAmyloid A protein
dc.subject.emtreeSerum amyloid A
dc.subject.emtreeTumor marker
dc.subject.emtreeAdult
dc.subject.emtreeArticle
dc.subject.emtreeCancer prognosis
dc.subject.emtreeCancer staging
dc.subject.emtreeCancer survival
dc.subject.emtreeControlled study
dc.subject.emtreeDisease course
dc.subject.emtreeFemale
dc.subject.emtreeHuman
dc.subject.emtreeHuman tissue
dc.subject.emtreeImmunohistochemistry
dc.subject.emtreeImmunoreactivity
dc.subject.emtreeKidney carcinoma
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeOverall survival
dc.subject.emtreePriority journal
dc.subject.emtreeAged
dc.subject.emtreeCancer grading
dc.subject.emtreeCarcinoma, renal cell
dc.subject.emtreeGene expression
dc.subject.emtreeGenetics
dc.subject.emtreeKidney
dc.subject.emtreeKidney neoplasms
dc.subject.emtreeMetabolism
dc.subject.emtreeMiddle aged
dc.subject.emtreeMortality
dc.subject.emtreeNephrectomy
dc.subject.emtreePathology
dc.subject.emtreePrognosis
dc.subject.emtreeProportional hazards model
dc.subject.emtreeTumor invasion
dc.subject.emtreeVery elderly
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBiomarkers, tumor
dc.subject.meshCarcinoma, renal cell
dc.subject.meshFemale
dc.subject.meshGene expression
dc.subject.meshHumans
dc.subject.meshImmunohistochemistry
dc.subject.meshKidney
dc.subject.meshKidney neoplasms
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshNeoplasm grading
dc.subject.meshNeoplasm invasiveness
dc.subject.meshNeoplasm staging
dc.subject.meshNephrectomy
dc.subject.meshPrognosis
dc.subject.meshProportional hazards models
dc.subject.meshSerum amyloid A protein
dc.subject.scopusProtein; Amyloidosis; Amyloid Enhancing Factor
dc.subject.wosImmunology
dc.subject.wosMicrobiology
dc.subject.wosPathology
dc.titleSignificance of amyloid A immunoexpression in the prognosis of renal cell carcinoma
dc.typeArticle
dc.wos.quartileQ4 (Immunology)
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Cerrahi Patoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Üroloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: